Abstract
Brentuximab vedotin (BV), a potent antibody-drug conjugate, targets the CD30 antigen. Owing to the remarkable efficacy shown in CD30-positive lymphomas, such as Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma, BV was granted accelerated approval in 2011 by the US Food and Drug Administration. Thereafter, many large-scale trials in various situations have been performed, which led to extensions of the original indication. The aim of this review was to describe the latest updates on clinical trials of BV and the in-practice guidance for the use of BV.
| Original language | English |
|---|---|
| Pages (from-to) | 243-253 |
| Number of pages | 11 |
| Journal | Blood Research |
| Volume | 52 |
| Issue number | 4 |
| DOIs | |
| State | Published - 2017 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Anaplastic large cell lymphoma
- Antibody-drug conjugate
- Brentuximab vedotin
- CD30
- Hodgkin's lymphoma
Fingerprint
Dive into the research topics of 'Brentuximab vedotin: Clinical updates and practical guidance'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver